文献速递瓣膜病与结构性心脏病

年度NT-proBNP检测与无症状非重度主动脉瓣狭窄临床事件的关联

Association of Annual N-Terminal Pro-Brain Natriuretic Peptide Measurements With Clinical Events in Patients With Asymptomatic Nonsevere Aortic Stenosis: A Post Hoc Substudy of the SEAS Trial.
PubMed 文献 · JAMA Cardiol · 2022-01-01

该研究为SEAS随机临床试验的事后分析,纳入1644例无症状非重度主动脉瓣狭窄患者,评估年度NT-proBNP检测与临床结局的关联。结果发现,1年时NT-proBNP正常者主动脉瓣事件和全因死亡率低,而NT-proBNP升高且较基线增加≥50%者事件率最高。

要点

  • 1年时NT-proBNP正常与较低主动脉瓣事件和全因死亡相关
  • NT-proBNP升高且较基线增加≥50%提示主动脉瓣事件风险高
  • 年度NT-proBNP检测或有助于无症状非重度AS的风险分层

核心结论

  • 1年随访时NT-proBNP正常与无症状非重度主动脉瓣狭窄患者较低的主动脉瓣事件和全因死亡率相关。
  • 1年NT-proBNP升高且较基线增加≥50%可能与高主动脉瓣事件率相关。

研究设计与样本

  • SEAS随机临床试验的事后分析,纳入1644例有基线和1年血样的无症状非重度主动脉瓣狭窄患者。

主要发现

  • 1年时校正NT-proBNP正常者中,轻度AS患者主动脉瓣事件率为1.39/100患者年,升高者为7.05/100患者年(P<.01)。
  • 中度AS患者中,1年校正NT-proBNP正常者主动脉瓣事件率为10.38/100患者年,升高者为26.20/100患者年(P<.01)。
  • 轻度AS患者中,1年校正NT-proBNP正常与升高者的全因死亡率分别为1.05和4.17/100患者年(P<.01)。
  • 中度AS患者中,1年校正NT-proBNP正常与升高者的全因死亡率分别为1.60和4.78/100患者年(P<.01)。
  • 1年校正NT-proBNP升高且较基线增加≥1.5倍与最高主动脉瓣事件率相关,轻度AS的HR为8.12(95%CI 3.53-18.66),中度AS的HR为4.05(95%CI 2.84-5.77)。

临床怎么用

  • 对无症状非重度主动脉瓣狭窄患者,可考虑年度检测NT-proBNP以辅助风险分层。
  • NT-proBNP正常提示低事件风险,升高且较基线增加≥50%提示需密切监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Recent studies have questioned the presumed low-risk status of patients with asymptomatic nonsevere aortic stenosis (AS). Whether annual N-terminal pro-brain natriuretic peptide (NT-proBNP) measurements are useful for risk assessment is unknown. OBJECTIVE: To assess the association of annual NT-proBNP measurements with clinical outcomes in patients with nonsevere AS. DESIGN, SETTING, AND PARTICIPANTS: Analysis of annual NT-proBNP concentrations in the multicenter, double-blind Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) randomized clinical trial was performed. SEAS was conducted from January 6, 2003, to April 1, 2008. Blood samples were analyzed in 2016, and data analysis was performed from February 10 to October 10, 2021. SEAS included 1873 patients with asymptomatic AS not requiring statin therapy with transaortic maximal flow velocity from 2.5 to 4.0 m/s and preserved ejection fraction. This substudy included 1644 patients (87.8%) with available blood samples at baseline and year 1. EXPOSURES: Increased age- and sex-adjusted NT-proBNP concentrations at year 1 and a 1.5-fold or greater relative NT-proBNP concentration change from baseline to year 1. Moderate AS was defined as baseline maximal flow velocity greater than or equal to 3.0 m/s. MAIN OUTCOMES AND MEASURES: Aortic valve events (AVEs), which are a composite of aortic valve replacement, cardiovascular death, or incident heart failure due to AS progression, were noted. Landmark analyses from year 1 examined the association of NT-proBNP concentrations with outcomes. RESULTS: Among 1644 patients, 996 were men (60.6%); mean (SD) age was 67.5 (9.7) years. Adjusted NT-proBNP concentrations were within the reference range (normal) in 1228 of 1594 patients (77.0%) with NT-proBNP values available at baseline and in 1164 of 1644 patients (70.8%) at year 1. During the next 2 years of follow-up, the AVE rates per 100 patient-years for normal vs increased adjusted NT-proBNP levels at year 1 were 1.39 (95% CI, 0.86-2.23) vs 7.05 (95% CI, 4.60-10.81) for patients with mild AS (P < .01), and 10.38 (95% CI, 8.56-12.59) vs 26.20 (95% CI, 22.03-31.15) for those with moderate AS (P < .01). Corresponding all-cause mortality rates were 1.05 (95% CI, 0.61-1.81) vs 4.17 (95% CI, 2.42-7.19) for patients with mild AS (P < .01), and 1.60 (95% CI, 0.99-2.57) vs 4.78 (95% CI, 3.32-6.87) for those with moderate AS (P < .01). In multivariable Cox proportional hazards regression models, the combination of a 1-year increased adjusted NT-proBNP level and 1.5-fold or greater NT-proBNP level change from baseline was associated with the highest AVE rates in both patients with mild AS (hazard ratio, 8.12; 95% CI, 3.53-18.66; P < .001) and those with moderate AS (hazard ratio, 4.05; 95% CI, 2.84-5.77; P < .001). CONCLUSIONS AND RELEVANCE: The findings of this study suggest that normal NT-proBNP concentrations at 1-year follow-up are associated with low AVE and all-cause mortality rates in patients with asymptomatic nonsevere AS. Conversely, an increased 1-year NT-proBNP level combined with a 50% or greater increase from baseline may be associated with high AVE rates. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00092677.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Hadziselimovic E, Greve AM, Sajadieh A, et al. Association of Annual N-Terminal Pro-Brain Natriuretic Peptide Measurements With Clinical Events in Patients With Asymptomatic Nonsevere Aortic Stenosis: A Post Hoc Substudy of the SEAS Trial. JAMA Cardiol. 2022. PMID: 35171199. doi:10.1001/jamacardio.2021.5916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。